Ra Capital Management, L.p. - Net Worth and Insider Trading

Ra Capital Management, L.p. Net Worth

The estimated net worth of Ra Capital Management, L.p. is at least $777 Million dollars as of 2024-11-05. Ra Capital Management, L.p. is the 10% Owner of TG Therapeutics Inc and owns about 12,629,868 shares of TG Therapeutics Inc (TGTX) stock worth over $308 Million. Ra Capital Management, L.p. is the Director, 10% Owner of WAVE Life Sciences Ltd and owns about 7,775,207 shares of WAVE Life Sciences Ltd (WVE) stock worth over $107 Million. Ra Capital Management, L.p. is also the 10% Owner of Pandion Therapeutics Inc and owns about 1,770,023 shares of Pandion Therapeutics Inc (PAND) stock worth over $106 Million. Besides these, Ra Capital Management, L.p. also holds BioSpecifics Technologies Corp (BSTC) , Dynegy Inc (DYN) , Achillion Pharmaceuticals Inc (ACHN) , ITeos Therapeutics Inc (ITOS) , Nkarta Inc (NKTX) , KalVista Pharmaceuticals Inc (KALV) , Derma Sciences Inc (DSCI) , Inozyme Pharma Inc (INZY) , Aclaris Therapeutics Inc (ACRS) , PMV Pharmaceuticals Inc (PMVP) , Curis Inc (CRIS) , Aradigm Corp (ARDMQ) . Details can be seen in Ra Capital Management, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ra Capital Management, L.p. has not made any transactions after 2020-09-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Ra Capital Management, L.p.

Ra Capital Management, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ra Capital Management, L.p. owns 62 companies in total, including Vaxcyte Inc (PCVX) , Cardiff Oncology Inc (CRDF) , and PMV Pharmaceuticals Inc (PMVP) among others .

Click here to see the complete history of Ra Capital Management, L.p.’s form 4 insider trades.

Insider Ownership Summary of Ra Capital Management, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
PCVX	Vaxcyte Inc	2020-06-16	10 percent owner
CRDF	Cardiff Oncology Inc	2020-09-30	10 percent owner
PMVP	PMV Pharmaceuticals Inc	2020-09-29	10 percent owner
		2020-09-16	10 percent owner
		2019-11-08	director & 10 percent owner
		2020-09-09	10 percent owner
		2020-08-18	10 percent owner
		2020-07-28	10 percent owner
		2020-07-28	10 percent owner
		2020-07-21	10 percent owner
		2020-07-14	10 percent owner
		2019-10-16	10 percent owner
		2020-06-25	10 percent owner
		2020-03-03	10 percent owner
		2020-06-18	10 percent owner
		2020-04-02	director & 10 percent owner
		2019-10-25	10 percent owner
		2020-03-11	10 percent owner
		2020-03-13	director & 10 percent owner
		2020-02-14	10 percent owner
		2020-01-23	10 percent owner
		2020-12-03	director & 10 percent owner
		2021-04-01	director & 10 percent owner
		2018-10-23	10 percent owner
		2018-09-26	10 percent owner
		2018-06-22	director
		2017-12-18	10 percent owner
		2017-10-12	director
		2017-05-16	director & 10 percent owner
		2016-09-16	10 percent owner
		2014-09-30	other: Former 10% Owner & See FN(5)(6)
		2013-06-26	10 percent owner
		2014-01-10	other: Fmr 10% Owner - See Fn (1)-(5)
		2010-02-26	10 percent owner
		2008-10-29	10 percent owner
		2008-07-10	10 percent owner
		2007-08-08	10 percent owner
		2021-08-03	10 percent owner
		2021-06-30	director & 10 percent owner
		2020-12-07	10 percent owner
		2021-09-14	director & 10 percent owner
		2020-11-22	10 percent owner
		2020-12-10	director & 10 percent owner
		2020-08-06	10 percent owner
		2021-08-09	director & 10 percent owner
		2021-04-29	director & 10 percent owner
		2021-07-28	director & 10 percent owner
		2021-06-29	director & 10 percent owner
		2021-06-23	director
		2021-02-04	director & 10 percent owner
		2021-06-10	director & 10 percent owner
		2021-07-22	director
		2022-05-05	director & 10 percent owner
		2021-09-14	director & 10 percent owner
		2022-03-24	10 percent owner
		2022-08-16	10 percent owner
		2022-11-08	director
		2022-11-09	director & 10 percent owner
		2022-11-08	director
		2020-03-11	10 percent owner
		2023-02-09	director & 10 percent owner
		2023-07-05	director

Ra Capital Management, L.p. Latest Holdings Summary

Ra Capital Management, L.p. currently owns a total of 15 stocks. Among these stocks, Ra Capital Management, L.p. owns 12,629,868 shares of TG Therapeutics Inc (TGTX) as of September 9, 2020, with a value of $308 Million and a weighting of 39.59%. Ra Capital Management, L.p. owns 7,775,207 shares of WAVE Life Sciences Ltd (WVE) as of January 24, 2019, with a value of $107 Million and a weighting of 13.8%. Ra Capital Management, L.p. also owns 1,770,023 shares of Pandion Therapeutics Inc (PAND) as of July 21, 2020, with a value of $106 Million and a weighting of 13.68%. The other 12 stocks BioSpecifics Technologies Corp (BSTC) , Dynegy Inc (DYN) , Achillion Pharmaceuticals Inc (ACHN) , ITeos Therapeutics Inc (ITOS) , Nkarta Inc (NKTX) , KalVista Pharmaceuticals Inc (KALV) , Derma Sciences Inc (DSCI) , Inozyme Pharma Inc (INZY) , Aclaris Therapeutics Inc (ACRS) , PMV Pharmaceuticals Inc (PMVP) , Curis Inc (CRIS) , Aradigm Corp (ARDMQ) have a combined weighting of 32.93% among all his current holdings.

Latest Holdings of Ra Capital Management, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TGTX	TG Therapeutics Inc	2020-09-09	12,629,868	24.36	307,663,584
WVE	WAVE Life Sciences Ltd	2019-01-24	7,775,207	13.79	107,220,105
PAND	Pandion Therapeutics Inc	2020-07-21	1,770,023	60.05	106,289,881
BSTC	BioSpecifics Technologies Corp	2010-02-26	626,462	88.53	55,460,681
DYN	Dynegy Inc	2020-09-21	2,805,045	18.61	52,201,887
ACHN	Achillion Pharmaceuticals Inc	2014-09-30	6,700,000	6.76	45,292,000
ITOS	ITeos Therapeutics Inc	2020-07-28	4,417,259	8.97	39,622,813
NKTX	Nkarta Inc	2020-07-14	5,605,129	3.23	18,104,567
KALV	KalVista Pharmaceuticals Inc	2017-10-12	1,441,070	11.63	16,759,644
DSCI	Derma Sciences Inc	2014-01-10	1,694,876	7.00	11,864,132
INZY	Inozyme Pharma Inc	2020-07-28	2,003,653	4.42	8,856,146
ACRS	Aclaris Therapeutics Inc	2016-09-16	2,102,169	2.17	4,561,707
PMVP	PMV Pharmaceuticals Inc	2020-09-29	1,710,265	1.64	2,804,835
CRIS	Curis Inc	2007-08-08	75,506	4.33	326,941
ARDMQ	Aradigm Corp	2007-01-24	158,875	0.05	7,308

Holding Weightings of Ra Capital Management, L.p.

Ra Capital Management, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 1 transactions in TG Therapeutics Inc (TGTX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in TG Therapeutics Inc is the sale of 158,589 shares on September 9, 2020, which brought Ra Capital Management, L.p. around $4 Million.

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 0 transactions in WAVE Life Sciences Ltd (WVE) over the past 5 years. The most-recent trade in WAVE Life Sciences Ltd is the acquisition of 263,158 shares on January 24, 2019, which cost Ra Capital Management, L.p. around $10 Million.

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 1 transactions in Pandion Therapeutics Inc (PAND) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pandion Therapeutics Inc is the acquisition of 361,111 shares on July 21, 2020, which cost Ra Capital Management, L.p. around $7 Million.

More details on Ra Capital Management, L.p.'s insider transactions can be found in the Insider Trading History of Ra Capital Management, L.p. table.

Insider Trading History of Ra Capital Management, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ra Capital Management, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Ra Capital Management, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ra Capital Management, L.p. is 20.46%. GuruFocus also compares Ra Capital Management, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Ra Capital Management, L.p. within 3 months outperforms 26 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ra Capital Management, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ra Capital Management, L.p.

Average Return

Average return per transaction

Outperforming Transactions

31 out of 36 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	9.75
Relative Return to S&P 500(%)	7.57

Ra Capital Management, L.p. Ownership Network

Ownership Network List of Ra Capital Management, L.p.

No Data

Ownership Network Relation of Ra Capital Management, L.p.

Ra Capital Management, L.p. Owned Company Details

What does Vaxcyte Inc do?

Who are the key executives at Vaxcyte Inc?

Ra Capital Management, L.p. is the 10 percent owner of Vaxcyte Inc. Other key executives at Vaxcyte Inc include Chief Operating Officer Jim Wassil , director & President & CEO Grant Pickering , and CFO & CBO Andrew Guggenhime .

Vaxcyte Inc (PCVX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Vaxcyte Inc (PCVX). Other recent insider transactions involving Vaxcyte Inc (PCVX) include a net sale of 268,266 shares made by Grant Pickering , a net sale of 152,000 shares made by Andrew Guggenhime , and a net sale of 66,000 shares made by Jim Wassil .

In summary, during the past 3 months, insiders sold 209,515 shares of Vaxcyte Inc (PCVX) in total and bought 0 shares, with a net sale of 209,515 shares. During the past 18 months, 598,563 shares of Vaxcyte Inc (PCVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 598,563 shares.

Vaxcyte Inc (PCVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vaxcyte Inc Insider Transactions

No Available Data

What does Cardiff Oncology Inc do?

Who are the key executives at Cardiff Oncology Inc?

Ra Capital Management, L.p. is the 10 percent owner of Cardiff Oncology Inc. Other key executives at Cardiff Oncology Inc include Chief Medical Officer Fairooz Kabbinavar , Chief Scientific Officer Mark Erlander , and Chief Financial Officer James E. Levine .

Cardiff Oncology Inc (CRDF) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Cardiff Oncology Inc (CRDF). Other recent insider transactions involving Cardiff Oncology Inc (CRDF) include a net purchase of 52,950 shares made by Gary W Pace ,

In summary, during the past 3 months, insiders sold 0 shares of Cardiff Oncology Inc (CRDF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cardiff Oncology Inc (CRDF) were sold and 52,950 shares were bought by its insiders, resulting in a net purchase of 52,950 shares.

Cardiff Oncology Inc (CRDF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cardiff Oncology Inc Insider Transactions

No Available Data

What does PMV Pharmaceuticals Inc do?

Who are the key executives at PMV Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of PMV Pharmaceuticals Inc. Other key executives at PMV Pharmaceuticals Inc include SVP & Regulatory Affairs and QA Deepika Jalota , 10 percent owner Orbimed Advisors Llc , and Chief Medical Officer Leila Alland .

PMV Pharmaceuticals Inc (PMVP) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in PMV Pharmaceuticals Inc (PMVP). Other recent insider transactions involving PMV Pharmaceuticals Inc (PMVP) include a net sale of 11,322 shares made by Deepika Jalota , a net sale of 87,786 shares made by Orbimed Advisors Llc , and a net sale of 6,291 shares made by Leila Alland .

In summary, during the past 3 months, insiders sold 10,109 shares of PMV Pharmaceuticals Inc (PMVP) in total and bought 0 shares, with a net sale of 10,109 shares. During the past 18 months, 108,290 shares of PMV Pharmaceuticals Inc (PMVP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 108,290 shares.

PMV Pharmaceuticals Inc (PMVP)'s detailed insider trading history can be found in Insider Trading Tracker table.

PMV Pharmaceuticals Inc Insider Transactions

No Available Data

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include director & 10 percent owner Dirk Kersten , See Remarks Richard William Scalzo , and Chief Operating Officer Susanna Gatti High .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Dyne Therapeutics Inc (DYN). Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 446,445 shares made by Dirk Kersten , a net sale of 327,516 shares made by Richard William Scalzo , and a net sale of 273,683 shares made by Susanna Gatti High .

In summary, during the past 3 months, insiders sold 2,321,732 shares of Dyne Therapeutics Inc (DYN) in total and bought 32,000 shares, with a net sale of 2,289,732 shares. During the past 18 months, 7,985,414 shares of Dyne Therapeutics Inc (DYN) were sold and 1,746,285 shares were bought by its insiders, resulting in a net sale of 6,239,129 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dyne Therapeutics Inc Insider Transactions

No Available Data

What does 89bio Inc do?

Who are the key executives at 89bio Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of 89bio Inc. Other key executives at 89bio Inc include See Remarks Quoc Le-nguyen , director & Chief Executive Officer Rohan Palekar , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

89bio Inc (ETNB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in 89bio Inc (ETNB). Other recent insider transactions involving 89bio Inc (ETNB) include a net sale of 72,195 shares made by Rohan Palekar , a net sale of 41,638 shares made by Quoc Le-nguyen , and a net purchase of 1,350,000 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 27,955 shares of 89bio Inc (ETNB) in total and bought 0 shares, with a net sale of 27,955 shares. During the past 18 months, 132,583 shares of 89bio Inc (ETNB) were sold and 1,350,000 shares were bought by its insiders, resulting in a net purchase of 1,217,417 shares.

89bio Inc (ETNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

89bio Inc Insider Transactions

No Available Data

What does TG Therapeutics Inc do?

Who are the key executives at TG Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of TG Therapeutics Inc. Other key executives at TG Therapeutics Inc include CFO & Secretary and Treasurer Sean A Power , director & CEO and President Michael S Weiss , and 10 percent owner Peter Kolchinsky .

TG Therapeutics Inc (TGTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in TG Therapeutics Inc (TGTX). Other recent insider transactions involving TG Therapeutics Inc (TGTX) include a net sale of 65,787 shares made by Sagar Lonial , a net sale of 121,514 shares made by Sean A Power , and a net sale of 39,500 shares made by Laurence N Charney .

In summary, during the past 3 months, insiders sold 0 shares of TG Therapeutics Inc (TGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 226,801 shares of TG Therapeutics Inc (TGTX) were sold and 100,000 shares were bought by its insiders, resulting in a net sale of 126,801 shares.

TG Therapeutics Inc (TGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

TG Therapeutics Inc Insider Transactions

No Available Data

What does Inhibrx Inc do?

Who are the key executives at Inhibrx Inc?

Ra Capital Management, L.p. is the 10 percent owner of Inhibrx Inc. Other key executives at Inhibrx Inc include director & 10 percent owner & Chief Scientific Officer Brendan P. Eckelman , 10 percent owner Ole Andreas Halvorsen , and 10 percent owner Viking Global Opportunities Parent Gp Llc .

Inhibrx Inc (INBX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Inhibrx Inc (INBX). Other recent insider transactions involving Inhibrx Inc (INBX) include a net purchase of 511,627 shares made by Viking Global Investors Lp , and a net sale of 300,000 shares made by Brendan P. Eckelman .

In summary, during the past 3 months, insiders sold 0 shares of Inhibrx Inc (INBX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 300,000 shares of Inhibrx Inc (INBX) were sold and 511,627 shares were bought by its insiders, resulting in a net purchase of 211,627 shares.

Inhibrx Inc (INBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inhibrx Inc Insider Transactions

No Available Data

What does Inozyme Pharma Inc do?

Who are the key executives at Inozyme Pharma Inc?

Ra Capital Management, L.p. is the 10 percent owner of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and 10 percent owner Longitude Capital Partners Iii, Llc .

Inozyme Pharma Inc (INZY) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,281,265 shares made by Robert Lorne Hopfner , a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , and a net sale of 7,523 shares made by Douglas A Treco .

In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,114,598 shares were bought by its insiders, resulting in a net purchase of 2,107,075 shares.

Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inozyme Pharma Inc Insider Transactions

No Available Data

What does ITeos Therapeutics Inc do?

Who are the key executives at ITeos Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include Chief Financial Officer Matthew Gall , other: See remarks Joseph Lewis , and other: See remarks Boxer Asset Management Inc. .

ITeos Therapeutics Inc (ITOS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in ITeos Therapeutics Inc (ITOS). Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net sale of 350,000 shares made by Boxer Capital, Llc , and a net purchase of 5,000 shares made by Matthew Gall .

In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 345,000 shares.

ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

ITeos Therapeutics Inc Insider Transactions

No Available Data

What does Pandion Therapeutics Inc do?

Who are the key executives at Pandion Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Pandion Therapeutics Inc. Other key executives at Pandion Therapeutics Inc include director & 10 percent owner Daniel J. Becker , 10 percent owner Mva Investors, Llc , and 10 percent owner Polaris Partners VIII, L.P. .

Pandion Therapeutics Inc (PAND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pandion Therapeutics Inc (PAND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pandion Therapeutics Inc (PAND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pandion Therapeutics Inc (PAND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pandion Therapeutics Inc Insider Transactions

No Available Data

What does Nkarta Inc do?

Who are the key executives at Nkarta Inc?

Ra Capital Management, L.p. is the 10 percent owner of Nkarta Inc. Other key executives at Nkarta Inc include Chief Legal Officer Alicia J. Hager , Chief Medical Officer David Shook , and Sr. VP & Technical Operations Ralph Brandenberger .

Nkarta Inc (NKTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Nkarta Inc (NKTX). Other recent insider transactions involving Nkarta Inc (NKTX) include a net sale of 9,598 shares made by James Trager , a net sale of 9,378 shares made by Alicia J. Hager , and a net sale of 5,778 shares made by David Shook .

In summary, during the past 3 months, insiders sold 0 shares of Nkarta Inc (NKTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 41,413 shares of Nkarta Inc (NKTX) were sold and 5,000,000 shares were bought by its insiders, resulting in a net purchase of 4,958,587 shares.

Nkarta Inc (NKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nkarta Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include Chief Human Resources Officer Pamela J. Cramer , Chief Technical Officer Joseph Shulman , and Corporate Controller & CAO Christopher Paul German .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 171,662 shares made by Joseph Shulman , a net sale of 78,894 shares made by Jennifer Chien , and a net sale of 75,787 shares made by Pamela J. Cramer .

In summary, during the past 3 months, insiders sold 174,805 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 174,805 shares. During the past 18 months, 582,666 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 582,666 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Ra Capital Management, L.p. is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Ra Capital Management, L.p. is the 10 percent owner of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 668 shares made by Daniel Calkins , a net sale of 20,888 shares made by Robert E. Gagnon , and a net sale of 5,805 shares made by Dan Paterson .

In summary, during the past 3 months, insiders sold 1,883 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 1,883 shares. During the past 18 months, 32,310 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 32,310 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does Forma Therapeutics Holdings Inc do?

Who are the key executives at Forma Therapeutics Holdings Inc?

Ra Capital Management, L.p. is the 10 percent owner of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .

Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forma Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Ra Pharmaceuticals Inc do?

Who are the key executives at Ra Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Ra Pharmaceuticals Inc. Other key executives at Ra Pharmaceuticals Inc include Executive VP and CFO David Charles Lubner , director & President and CEO Douglas A Treco , and 10 percent owner Scott D Sandell .

Ra Pharmaceuticals Inc (RARX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ra Pharmaceuticals Inc (RARX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ra Pharmaceuticals Inc (RARX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ra Pharmaceuticals Inc (RARX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ra Pharmaceuticals Inc Insider Transactions

No Available Data

What does Phathom Pharmaceuticals Inc do?

Who are the key executives at Phathom Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Phathom Pharmaceuticals Inc. Other key executives at Phathom Pharmaceuticals Inc include CFO and CBO Molly Henderson , Chief Operating Officer Azmi Nabulsi , and 10 percent owner Takeda Pharmaceutical Co Ltd .

Phathom Pharmaceuticals Inc (PHAT) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Phathom Pharmaceuticals Inc (PHAT). Other recent insider transactions involving Phathom Pharmaceuticals Inc (PHAT) include a net sale of 32,756 shares made by Molly Henderson , a net sale of 50,699 shares made by Terrie Curran , and a net sale of 3,703,703 shares made by Takeda Pharmaceutical Co Ltd .

In summary, during the past 3 months, insiders sold 0 shares of Phathom Pharmaceuticals Inc (PHAT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,798,059 shares of Phathom Pharmaceuticals Inc (PHAT) were sold and 7,500 shares were bought by its insiders, resulting in a net sale of 3,790,559 shares.

Phathom Pharmaceuticals Inc (PHAT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Phathom Pharmaceuticals Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

Ra Capital Management, L.p. is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Kala Bio Inc do?

Who are the key executives at Kala Bio Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Kala Bio Inc. Other key executives at Kala Bio Inc include CHIEF BUSINESS OFFICER Darius Kharabi , Chief Financial Officer Mary Reumuth , and director & Chief Executive Officer Mark T Iwicki .

Kala Bio Inc (KALA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Kala Bio Inc (KALA). Other recent insider transactions involving Kala Bio Inc (KALA) include a net sale of 27,099 shares made by Mark T Iwicki , a net sale of 9,108 shares made by Romulus K Brazzell , and a net sale of 8,151 shares made by Todd Bazemore .

In summary, during the past 3 months, insiders sold 0 shares of Kala Bio Inc (KALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 59,535 shares of Kala Bio Inc (KALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 59,535 shares.

Kala Bio Inc (KALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kala Bio Inc Insider Transactions

No Available Data

What does scPharmaceuticals Inc do?

Who are the key executives at scPharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of scPharmaceuticals Inc. Other key executives at scPharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , 10 percent owner 5am Partners Iv, Llc , and director & President and CEO John H Tucker .

scPharmaceuticals Inc (SCPH) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in scPharmaceuticals Inc (SCPH). Other recent insider transactions involving scPharmaceuticals Inc (SCPH) include a net purchase of 500,000 shares made by Orbimed Advisors Llc ,

In summary, during the past 3 months, insiders sold 0 shares of scPharmaceuticals Inc (SCPH) in total and bought 500,000 shares, with a net purchase of 500,000 shares. During the past 18 months, 0 shares of scPharmaceuticals Inc (SCPH) were sold and 500,000 shares were bought by its insiders, resulting in a net purchase of 500,000 shares.

scPharmaceuticals Inc (SCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

scPharmaceuticals Inc Insider Transactions

No Available Data

What does Synthorx Inc do?

Who are the key executives at Synthorx Inc?

Ra Capital Management, L.p. is the 10 percent owner of Synthorx Inc. Other key executives at Synthorx Inc include 10 percent owner Ra Capital Healthcare Fund Lp , director & 10 percent owner Peter Kolchinsky , and director & 10 percent owner Peter A. Thompson .

Synthorx Inc (THOR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Synthorx Inc (THOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Synthorx Inc (THOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Synthorx Inc (THOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synthorx Inc Insider Transactions

No Available Data

What does Satsuma Pharmaceuticals Inc do?

Who are the key executives at Satsuma Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Satsuma Pharmaceuticals Inc. Other key executives at Satsuma Pharmaceuticals Inc include 10 percent owner Shin Nippon Biomedical Laboratories, Ltd. , director & 10 percent owner Ken Takanashi , and 10 percent owner Braden Michael Leonard .

Satsuma Pharmaceuticals Inc (STSA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Satsuma Pharmaceuticals Inc (STSA). Other recent insider transactions involving Satsuma Pharmaceuticals Inc (STSA) include a net purchase of 30,477,313 shares made by Shin Nippon Biomedical Laboratories, Ltd. , and a net purchase of 22,053,581 shares made by Ken Takanashi .

In summary, during the past 3 months, insiders sold 0 shares of Satsuma Pharmaceuticals Inc (STSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Satsuma Pharmaceuticals Inc (STSA) were sold and 52,530,894 shares were bought by its insiders, resulting in a net purchase of 52,530,894 shares.

Satsuma Pharmaceuticals Inc (STSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Satsuma Pharmaceuticals Inc Insider Transactions

No Available Data

What does WAVE Life Sciences Ltd do?

Who are the key executives at WAVE Life Sciences Ltd?

Ra Capital Management, L.p. is the director & 10 percent owner of WAVE Life Sciences Ltd. Other key executives at WAVE Life Sciences Ltd include See Remarks Chris Francis , director & See Remarks Paul Bolno , and 10 percent owner Plc Glaxosmithkline .

WAVE Life Sciences Ltd (WVE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in WAVE Life Sciences Ltd (WVE). Other recent insider transactions involving WAVE Life Sciences Ltd (WVE) include a net sale of 69,838 shares made by Kyle Moran , a net purchase of 6,091,930 shares made by Plc Glaxosmithkline , and a net purchase of 2,000,000 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 364,822 shares of WAVE Life Sciences Ltd (WVE) in total and bought 2,791,930 shares, with a net purchase of 2,427,108 shares. During the past 18 months, 417,514 shares of WAVE Life Sciences Ltd (WVE) were sold and 8,091,930 shares were bought by its insiders, resulting in a net purchase of 7,674,416 shares.

WAVE Life Sciences Ltd (WVE)'s detailed insider trading history can be found in Insider Trading Tracker table.

WAVE Life Sciences Ltd Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Arvinas Inc do?

Who are the key executives at Arvinas Inc?

Ra Capital Management, L.p. is the 10 percent owner of Arvinas Inc. Other key executives at Arvinas Inc include Chief Medical Officer Ronald Peck , Chief Financial Officer Sean A Cassidy , and director & President and CEO John G Houston .

Arvinas Inc (ARVN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Arvinas Inc (ARVN). Other recent insider transactions involving Arvinas Inc (ARVN) include a net sale of 3,023 shares made by Ronald Peck , a net sale of 5,196 shares made by John G Houston , and a net sale of 1,702 shares made by Sean A Cassidy .

In summary, during the past 3 months, insiders sold 0 shares of Arvinas Inc (ARVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,622 shares of Arvinas Inc (ARVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,622 shares.

Arvinas Inc (ARVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arvinas Inc Insider Transactions

No Available Data

What does Eidos Therapeutics Inc do?

Who are the key executives at Eidos Therapeutics Inc?

Ra Capital Management, L.p. is the director of Eidos Therapeutics Inc. Other key executives at Eidos Therapeutics Inc include director & Chief Scientific Officer Uma Sinha , Senior Vice President & Finance Franco Valle , and Chief Business Officer Cameron Turtle .

Eidos Therapeutics Inc (EIDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eidos Therapeutics Inc (EIDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eidos Therapeutics Inc (EIDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eidos Therapeutics Inc (EIDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eidos Therapeutics Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Development Officer Christopher Yea .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 144,760 shares made by Benjamin L Palleiko , and a net sale of 116,267 shares made by Edward P. Feener .

In summary, during the past 3 months, insiders sold 40,693 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 40,693 shares. During the past 18 months, 583,370 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 667,647 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does G1 Therapeutics Inc do?

Who are the key executives at G1 Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of G1 Therapeutics Inc. Other key executives at G1 Therapeutics Inc include Chief Financial Officer John V. Umstead , Chief Commercial Officer Andrew Perry , and Chief Business Officer Mark Avagliano .

G1 Therapeutics Inc (GTHX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in G1 Therapeutics Inc (GTHX). Other recent insider transactions involving G1 Therapeutics Inc (GTHX) include a net sale of 78,166 shares made by Rajesh Malik , a net sale of 92,308 shares made by Bailey John E. (jack) Jr. , and a net sale of 15,968 shares made by John V. Umstead .

In summary, during the past 3 months, insiders sold 0 shares of G1 Therapeutics Inc (GTHX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 295,121 shares of G1 Therapeutics Inc (GTHX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 295,121 shares.

G1 Therapeutics Inc (GTHX)'s detailed insider trading history can be found in Insider Trading Tracker table.

G1 Therapeutics Inc Insider Transactions

No Available Data

What does Aclaris Therapeutics Inc do?

Who are the key executives at Aclaris Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .

Aclaris Therapeutics Inc (ACRS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net purchase of 4,854,052 shares made by Braden Michael Leonard , a net sale of 18,000 shares made by Joseph Monahan , and a net purchase of 14,705 shares made by James Loerop .

In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 18,000 shares of Aclaris Therapeutics Inc (ACRS) were sold and 4,878,247 shares were bought by its insiders, resulting in a net purchase of 4,860,247 shares.

Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aclaris Therapeutics Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Ra Capital Management, L.p. is the other: Former 10% Owner & See FN(5)(6) of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc (SGMO) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Sangamo Therapeutics Inc (SGMO). Other recent insider transactions involving Sangamo Therapeutics Inc (SGMO) include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc (SGMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc (SGMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc (SGMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sangamo Therapeutics Inc Insider Transactions

No Available Data

What does Derma Sciences Inc do?

Who are the key executives at Derma Sciences Inc?

Ra Capital Management, L.p. is the other: Fmr 10% Owner - See Fn (1)-(5) of Derma Sciences Inc. Other key executives at Derma Sciences Inc include director & other: Executive Chairman Stephen T Wills , other: Former Director Bruce F Wesson , and other: Former Director Amy S Paul .

Derma Sciences Inc (DSCI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Derma Sciences Inc (DSCI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Derma Sciences Inc (DSCI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Derma Sciences Inc (DSCI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Derma Sciences Inc Insider Transactions

No Available Data

What does BioSpecifics Technologies Corp do?

Who are the key executives at BioSpecifics Technologies Corp?

Ra Capital Management, L.p. is the 10 percent owner of BioSpecifics Technologies Corp. Other key executives at BioSpecifics Technologies Corp include director & 10 percent owner Toby Wegman , director & Chief Executive Officer Joseph Truitt , and Chief Financial Officer Patrick Hutchison .

BioSpecifics Technologies Corp (BSTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioSpecifics Technologies Corp (BSTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioSpecifics Technologies Corp (BSTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioSpecifics Technologies Corp (BSTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioSpecifics Technologies Corp Insider Transactions

No Available Data

What does Aradigm Corp do?

Who are the key executives at Aradigm Corp?

Ra Capital Management, L.p. is the 10 percent owner of Aradigm Corp. Other key executives at Aradigm Corp include 10 percent owner Bleichroeder Lp , 10 percent owner First Eagle Investment Management, Llc , and 10 percent owner First Eagle Value In Biotechnology Master Fund, Ltd. .

Aradigm Corp (ARDMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aradigm Corp (ARDMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aradigm Corp (ARDMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aradigm Corp (ARDMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aradigm Corp Insider Transactions

No Available Data

What does Sequenom Inc do?

Who are the key executives at Sequenom Inc?

Ra Capital Management, L.p. is the 10 percent owner of Sequenom Inc. Other key executives at Sequenom Inc include director & EVP and Treasurer Glenn A Eisenberg , director & Chairman & President & Sec Eberts F Samuel Iii , and Sr VP & GC & Secretary Jeffrey D Linton .

Sequenom Inc (SQNM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sequenom Inc (SQNM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sequenom Inc (SQNM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sequenom Inc (SQNM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sequenom Inc Insider Transactions

No Available Data

What does Curis Inc do?

Who are the key executives at Curis Inc?

Ra Capital Management, L.p. is the 10 percent owner of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and Head of Research & Development Robert Martell .

Curis Inc (CRIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Curis Inc Insider Transactions

No Available Data

What does RxSight Inc do?

Who are the key executives at RxSight Inc?

Ra Capital Management, L.p. is the 10 percent owner of RxSight Inc. Other key executives at RxSight Inc include Chief Operating Officer Ilya Goldshleger , director & See Remarks Kurtz Ronald M Md , and Chief Financial Officer Shelley B Thunen .

RxSight Inc (RXST) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in RxSight Inc (RXST). Other recent insider transactions involving RxSight Inc (RXST) include a net sale of 142,051 shares made by Ilya Goldshleger , a net sale of 1,063,606 shares made by Bakker Juliet Tammenoms , and a net sale of 50,000 shares made by Eric Weinberg .

In summary, during the past 3 months, insiders sold 49,620 shares of RxSight Inc (RXST) in total and bought 0 shares, with a net sale of 49,620 shares. During the past 18 months, 1,629,163 shares of RxSight Inc (RXST) were sold and 13,000 shares were bought by its insiders, resulting in a net sale of 1,616,163 shares.

RxSight Inc (RXST)'s detailed insider trading history can be found in Insider Trading Tracker table.

RxSight Inc Insider Transactions

No Available Data

What does Acumen Pharmaceuticals Inc do?

Who are the key executives at Acumen Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Acumen Pharmaceuticals Inc. Other key executives at Acumen Pharmaceuticals Inc include Chief Legal Office & Corp Sec Derek M Meisner , director & President and CEO Daniel Joseph Oconnell , and Chief Financial Officer Matt Zuga .

Acumen Pharmaceuticals Inc (ABOS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Acumen Pharmaceuticals Inc (ABOS). Other recent insider transactions involving Acumen Pharmaceuticals Inc (ABOS) include a net purchase of 5,161,290 shares made by Ra Capital Healthcare Fund Lp , a net sale of 41,949 shares made by Jeffrey L. Ives , and a net sale of 15,200 shares made by Daniel Joseph Oconnell .

In summary, during the past 3 months, insiders sold 0 shares of Acumen Pharmaceuticals Inc (ABOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 76,281 shares of Acumen Pharmaceuticals Inc (ABOS) were sold and 5,161,290 shares were bought by its insiders, resulting in a net purchase of 5,085,009 shares.

Acumen Pharmaceuticals Inc (ABOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acumen Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viridian Therapeutics Inc do?

Who are the key executives at Viridian Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Viridian Therapeutics Inc. Other key executives at Viridian Therapeutics Inc include director & President and CEO Stephen F. Mahoney , Chief Operating Officer Thomas W. Beetham , and director & other: See Remarks Fairmount Healthcare Fund Ii Gp Llc .

Viridian Therapeutics Inc (VRDN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Viridian Therapeutics Inc (VRDN). Other recent insider transactions involving Viridian Therapeutics Inc (VRDN) include a net sale of 9,796 shares made by Lara Meisner , a net purchase of 1,600,000 shares made by Fairmount Healthcare Fund Ii Gp Llc , and a net purchase of 476,190 shares made by Fairmount Healthcare Fund Gp Llc .

In summary, during the past 3 months, insiders sold 0 shares of Viridian Therapeutics Inc (VRDN) in total and bought 1,626,400 shares, with a net purchase of 1,626,400 shares. During the past 18 months, 9,796 shares of Viridian Therapeutics Inc (VRDN) were sold and 2,102,590 shares were bought by its insiders, resulting in a net purchase of 2,092,794 shares.

Viridian Therapeutics Inc (VRDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viridian Therapeutics Inc Insider Transactions

No Available Data

What does DICE Therapeutics Inc do?

Who are the key executives at DICE Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of DICE Therapeutics Inc. Other key executives at DICE Therapeutics Inc include 10 percent owner Northpond Ventures Gp, Llc , CSO John R. Jacobsen , and director & CEO Kevin Judice .

DICE Therapeutics Inc (DICE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in DICE Therapeutics Inc (DICE). Other recent insider transactions involving DICE Therapeutics Inc (DICE) include a net sale of 2,492,871 shares made by Northpond Ventures Gp, Llc , and a net sale of 18,750 shares made by John R. Jacobsen .

In summary, during the past 3 months, insiders sold 0 shares of DICE Therapeutics Inc (DICE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,511,621 shares of DICE Therapeutics Inc (DICE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,511,621 shares.

DICE Therapeutics Inc (DICE)'s detailed insider trading history can be found in Insider Trading Tracker table.

DICE Therapeutics Inc Insider Transactions

No Available Data

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Ra Capital Management, L.p. is the 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iterum Therapeutics PLC Insider Transactions

No Available Data

What does Solid Biosciences Inc do?

Who are the key executives at Solid Biosciences Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Solid Biosciences Inc. Other key executives at Solid Biosciences Inc include Chief Medical Officer Gabriel Brooks , director & Chief Executive Officer Ilan Ganot , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

Solid Biosciences Inc (SLDB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Solid Biosciences Inc (SLDB). Other recent insider transactions involving Solid Biosciences Inc (SLDB) include a net sale of 1,743 shares made by Ilan Ganot , a net purchase of 3,410,713 shares made by Perceptive Life Sciences Master Fund Ltd , and a net purchase of 904,160 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 2,923 shares of Solid Biosciences Inc (SLDB) in total and bought 0 shares, with a net sale of 2,923 shares. During the past 18 months, 26,705 shares of Solid Biosciences Inc (SLDB) were sold and 4,315,973 shares were bought by its insiders, resulting in a net purchase of 4,289,268 shares.

Solid Biosciences Inc (SLDB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Solid Biosciences Inc Insider Transactions

No Available Data

What does Orchard Therapeutics PLC do?

Who are the key executives at Orchard Therapeutics PLC?

Ra Capital Management, L.p. is the 10 percent owner of Orchard Therapeutics PLC. Other key executives at Orchard Therapeutics PLC include director & See Remarks Bobby Gaspar , 10 percent owner & other: See Remark 1 Fmr Llc , and 10 percent owner Ra Capital Healthcare Fund Lp .

Orchard Therapeutics PLC (ORTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Orchard Therapeutics PLC (ORTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Orchard Therapeutics PLC (ORTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Orchard Therapeutics PLC (ORTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Orchard Therapeutics PLC Insider Transactions

No Available Data

What does Climb Bio Inc do?

Who are the key executives at Climb Bio Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Climb Bio Inc. Other key executives at Climb Bio Inc include Chief Accounting Officer Emily Pimblett , Chief Scientific Officer Valerie Morisset , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

Climb Bio Inc (CLYM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Climb Bio Inc (CLYM). Other recent insider transactions involving Climb Bio Inc (CLYM) include a net sale of 481,639 shares made by Valerie Morisset , a net sale of 2,436 shares made by Emily Pimblett , and a net purchase of 13,008,546 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 1,191 shares of Climb Bio Inc (CLYM) in total and bought 0 shares, with a net sale of 1,191 shares. During the past 18 months, 484,075 shares of Climb Bio Inc (CLYM) were sold and 13,008,546 shares were bought by its insiders, resulting in a net purchase of 12,524,471 shares.

Climb Bio Inc (CLYM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Climb Bio Inc Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

What does Icosavax Inc do?

Who are the key executives at Icosavax Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include director & Chief Executive Officer Adam K. Simpson , Chief Financial Officer Thomas Joseph Russo , and Chief Medical Officer Niranjan Kanesa-thasan .

Icosavax Inc (ICVX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Icosavax Inc (ICVX). Other recent insider transactions involving Icosavax Inc (ICVX) include a net sale of 193,993 shares made by Adam K. Simpson , a net sale of 28,581 shares made by Cassia Cearley , and a net sale of 18,249 shares made by Thomas Joseph Russo .

In summary, during the past 3 months, insiders sold 0 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 272,386 shares of Icosavax Inc (ICVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 272,386 shares.

Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Icosavax Inc Insider Transactions

No Available Data

What does Aerovate Therapeutics Inc do?

Who are the key executives at Aerovate Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Aerovate Therapeutics Inc. Other key executives at Aerovate Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , See Remarks George A Eldridge , and SENIOR VICE PRESIDENT & CMC Marinus Verwijs .

Aerovate Therapeutics Inc (AVTE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Aerovate Therapeutics Inc (AVTE). Other recent insider transactions involving Aerovate Therapeutics Inc (AVTE) include a net sale of 64,255 shares made by Hunter Gillies , a net sale of 142,001 shares made by Benjamin T Dake , and a net sale of 62,449 shares made by Timothy P Noyes .

In summary, during the past 3 months, insiders sold 0 shares of Aerovate Therapeutics Inc (AVTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 401,833 shares of Aerovate Therapeutics Inc (AVTE) were sold and 928,110 shares were bought by its insiders, resulting in a net purchase of 526,277 shares.

Aerovate Therapeutics Inc (AVTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerovate Therapeutics Inc Insider Transactions

No Available Data

What does POINT Biopharma Global Inc do?

Who are the key executives at POINT Biopharma Global Inc?

Ra Capital Management, L.p. is the director of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Gp Holdings Llc .

POINT Biopharma Global Inc (PNT) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P ,

In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,161,278 shares.

POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.

POINT Biopharma Global Inc Insider Transactions

No Available Data

What does Vor Biopharma Inc do?

Who are the key executives at Vor Biopharma Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Vor Biopharma Inc. Other key executives at Vor Biopharma Inc include Chief Medical Officer Eyal C. Attar , director & 10 percent owner Kush Parmar , and 10 percent owner 5am Ventures Vi, L.p. .

Vor Biopharma Inc (VOR) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Vor Biopharma Inc (VOR). Other recent insider transactions involving Vor Biopharma Inc (VOR) include a net sale of 14,645 shares made by Eyal C. Attar ,

In summary, during the past 3 months, insiders sold 0 shares of Vor Biopharma Inc (VOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,645 shares of Vor Biopharma Inc (VOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 14,645 shares.

Vor Biopharma Inc (VOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vor Biopharma Inc Insider Transactions

No Available Data

What does Janux Therapeutics Inc do?

Who are the key executives at Janux Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Janux Therapeutics Inc. Other key executives at Janux Therapeutics Inc include director & Chief Executive Officer David Alan Campbell , director & 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Avalon Ventures Xi, L.p. .

Janux Therapeutics Inc (JANX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Janux Therapeutics Inc (JANX). Other recent insider transactions involving Janux Therapeutics Inc (JANX) include a net sale of 3,324,326 shares made by Avalon Ventures Xi, L.p. , a net sale of 653,961 shares made by Jay Lichter , and a net purchase of 1,695,008 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 2,782,995 shares of Janux Therapeutics Inc (JANX) in total and bought 1,200,000 shares, with a net sale of 1,582,995 shares. During the past 18 months, 6,605,716 shares of Janux Therapeutics Inc (JANX) were sold and 4,244,570 shares were bought by its insiders, resulting in a net sale of 2,361,146 shares.

Janux Therapeutics Inc (JANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Janux Therapeutics Inc Insider Transactions

No Available Data

What does Cytek Biosciences Inc do?

Who are the key executives at Cytek Biosciences Inc?

Ra Capital Management, L.p. is the director of Cytek Biosciences Inc. Other key executives at Cytek Biosciences Inc include director & Chief Technology Officer Ming Yan , Chief Financial Officer Patrick Jeanmonod , and director & President and CEO Wenbin Jiang .

Cytek Biosciences Inc (CTKB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Cytek Biosciences Inc (CTKB). Other recent insider transactions involving Cytek Biosciences Inc (CTKB) include a net sale of 221,900 shares made by Ming Yan , a net sale of 24,000 shares made by Patrick Jeanmonod , and a net sale of 140,000 shares made by Wenbin Jiang .

In summary, during the past 3 months, insiders sold 0 shares of Cytek Biosciences Inc (CTKB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 385,900 shares of Cytek Biosciences Inc (CTKB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 385,900 shares.

Cytek Biosciences Inc (CTKB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cytek Biosciences Inc Insider Transactions

No Available Data

What does PepGen Inc do?

Who are the key executives at PepGen Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of PepGen Inc. Other key executives at PepGen Inc include See Remarks Michelle L Mellion , See Remarks Niels Svenstrup , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

PepGen Inc (PEPG) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in PepGen Inc (PEPG). Other recent insider transactions involving PepGen Inc (PEPG) include a net sale of 50,000 shares made by Michelle L Mellion , a net sale of 29,556 shares made by James G Mcarthur , and a net purchase of 2,557,593 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of PepGen Inc (PEPG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 91,250 shares of PepGen Inc (PEPG) were sold and 2,559,287 shares were bought by its insiders, resulting in a net purchase of 2,468,037 shares.

PepGen Inc (PEPG)'s detailed insider trading history can be found in Insider Trading Tracker table.

PepGen Inc Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Chief Financial Officer Alan Fuhrman , director & Chief Executive Officer Todd Harris , and Chief Operating Officer Daniel Bensen .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 239,292 shares made by Daniel Bensen , a net sale of 370,700 shares made by Todd Harris , and a net sale of 138,711 shares made by Nina S Kjellson .

In summary, during the past 3 months, insiders sold 288,711 shares of Tyra Biosciences Inc (TYRA) in total and bought 9,500 shares, with a net sale of 279,211 shares. During the past 18 months, 748,703 shares of Tyra Biosciences Inc (TYRA) were sold and 9,500 shares were bought by its insiders, resulting in a net sale of 739,203 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

What does AN2 Therapeutics Inc do?

Who are the key executives at AN2 Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Ra Capital Healthcare Fund Lp , 10 percent owner Adjuvant Global Health Technology Fund De, L.p. , and Chief Strategy Officer Kevin Michael Krause .

AN2 Therapeutics Inc (ANTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in AN2 Therapeutics Inc (ANTX). Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Adjuvant Global Health Technology Fund De, L.p. , a net sale of 223,880 shares made by Kabeer Aziz , and a net sale of 1,747,316 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 3,525,094 shares of AN2 Therapeutics Inc (ANTX) in total and bought 1,500,000 shares, with a net sale of 2,025,094 shares. During the past 18 months, 4,090,725 shares of AN2 Therapeutics Inc (ANTX) were sold and 3,287,778 shares were bought by its insiders, resulting in a net sale of 802,947 shares.

AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

AN2 Therapeutics Inc Insider Transactions

No Available Data

What does Fulcrum Therapeutics Inc do?

Who are the key executives at Fulcrum Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Fulcrum Therapeutics Inc. Other key executives at Fulcrum Therapeutics Inc include Controller Greg Tourangeau , director & See Remarks Alex Sapir , and Chief Financial Officer Alan A Musso .

Fulcrum Therapeutics Inc (FULC) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Fulcrum Therapeutics Inc (FULC). Other recent insider transactions involving Fulcrum Therapeutics Inc (FULC) include a net sale of 5,330 shares made by Greg Tourangeau , and a net purchase of 43,360 shares made by Alex Sapir .

In summary, during the past 3 months, insiders sold 0 shares of Fulcrum Therapeutics Inc (FULC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,330 shares of Fulcrum Therapeutics Inc (FULC) were sold and 43,360 shares were bought by its insiders, resulting in a net purchase of 38,030 shares.

Fulcrum Therapeutics Inc (FULC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fulcrum Therapeutics Inc Insider Transactions

No Available Data

What does Silverback Therapeutics Inc do?

Who are the key executives at Silverback Therapeutics Inc?

Ra Capital Management, L.p. is the director of Silverback Therapeutics Inc. Other key executives at Silverback Therapeutics Inc include Chief Operating Officer Brian Dorsey , Chief Legal Officer Alexander A Fitzpatrick , and director & 10 percent owner & other: * Director by deputization Deerfield Management Company, L.p. (series C) .

Silverback Therapeutics Inc (SBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Silverback Therapeutics Inc (SBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Silverback Therapeutics Inc (SBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Silverback Therapeutics Inc (SBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Silverback Therapeutics Inc Insider Transactions

No Available Data

What does Acrivon Therapeutics Inc do?

Who are the key executives at Acrivon Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Acrivon Therapeutics Inc. Other key executives at Acrivon Therapeutics Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Legal Officer Mary Miller , and director & President and CEO Peter Blume-jensen .

Acrivon Therapeutics Inc (ACRV) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Acrivon Therapeutics Inc (ACRV). Other recent insider transactions involving Acrivon Therapeutics Inc (ACRV) include a net sale of 7,965 shares made by Chione Ltd , and a net purchase of 2,353,000 shares made by Perceptive Life Sciences Master Fund Ltd .

In summary, during the past 3 months, insiders sold 0 shares of Acrivon Therapeutics Inc (ACRV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,965 shares of Acrivon Therapeutics Inc (ACRV) were sold and 2,353,000 shares were bought by its insiders, resulting in a net purchase of 2,345,035 shares.

Acrivon Therapeutics Inc (ACRV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acrivon Therapeutics Inc Insider Transactions

No Available Data

What does ARS Pharmaceuticals Inc do?

Who are the key executives at ARS Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director of ARS Pharmaceuticals Inc. Other key executives at ARS Pharmaceuticals Inc include Chief Financial Officer Kathleen D. Scott , 10 percent owner & Chief Medical Officer Sarina Tanimoto , and director & 10 percent owner & President and CEO Richard E Lowenthal .

ARS Pharmaceuticals Inc (SPRY) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in ARS Pharmaceuticals Inc (SPRY). Other recent insider transactions involving ARS Pharmaceuticals Inc (SPRY) include a net sale of 1,603,260 shares made by Sarina Tanimoto , a net sale of 1,603,260 shares made by Richard E Lowenthal , and a net sale of 543,896 shares made by Laura Shawver .

In summary, during the past 3 months, insiders sold 3,229,754 shares of ARS Pharmaceuticals Inc (SPRY) in total and bought 0 shares, with a net sale of 3,229,754 shares. During the past 18 months, 5,780,170 shares of ARS Pharmaceuticals Inc (SPRY) were sold and 8,937,557 shares were bought by its insiders, resulting in a net purchase of 3,157,387 shares.

ARS Pharmaceuticals Inc (SPRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARS Pharmaceuticals Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 240,342 shares made by Samuel Kintz , a net sale of 239,847 shares made by Joseph P Lyssikatos , and a net sale of 88,314 shares made by Benjamin Hohl .

In summary, during the past 3 months, insiders sold 183,359 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 183,359 shares. During the past 18 months, 4,855,709 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,855,709 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

What does Mineralys Therapeutics Inc do?

Who are the key executives at Mineralys Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Mineralys Therapeutics Inc. Other key executives at Mineralys Therapeutics Inc include director & Chief Executive Officer Jon Congleton , CFO & Chief Bus. Off. and Secy. Adam Scott Levy , and 10 percent owner Catalys Pacific Fund, Lp .

Mineralys Therapeutics Inc (MLYS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Mineralys Therapeutics Inc (MLYS). Other recent insider transactions involving Mineralys Therapeutics Inc (MLYS) include a net sale of 142,377 shares made by Jon Congleton , a net sale of 232,341 shares made by David Malcom Rodman , and a net sale of 118,329 shares made by Adam Scott Levy .

In summary, during the past 3 months, insiders sold 26,028 shares of Mineralys Therapeutics Inc (MLYS) in total and bought 0 shares, with a net sale of 26,028 shares. During the past 18 months, 1,053,797 shares of Mineralys Therapeutics Inc (MLYS) were sold and 566,305 shares were bought by its insiders, resulting in a net sale of 487,492 shares.

Mineralys Therapeutics Inc (MLYS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mineralys Therapeutics Inc Insider Transactions

No Available Data

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

Ra Capital Management, L.p. is the director of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , 10 percent owner Biotech Growth N V , and director & 10 percent owner Ali Behbahani .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 221,600 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 221,600 shares. During the past 18 months, 246,600 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,075,850 shares were bought by its insiders, resulting in a net purchase of 4,829,250 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

Ra Capital Management, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Ra Capital Management, L.p.. You might contact Ra Capital Management, L.p. via mailing address: 200 Berkeley Street, 18th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.